| Filed On | Filing |
|---|---|
| 27 Oct 2026 | DEFM14A |
| 09 Oct 2026 |
8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On November 24, 2025, the Board of Directors (“the Board”), subject to the requisite approval of the shareholders of Impact BioMedical Inc. (the “Company”), approved a proposal to authorize a reverse stock split of the Company’s common s... |
| 24 Sep 2026 |
Form 4: DSS, Inc., 10% owner
Sold 723 shares ($398) · Sold 27 shares ($188) · Sold 156 shares ($1.1K) |
| 17 Sep 2026 | 425 |
| 17 Sep 2026 |
8-K: Regulation FD Disclosure
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Limited (f/k/a Dr Ashleys Limited) |
| 15 Sep 2026 | 425 |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited) |
| 07 Aug 2026 | 10-Q |
| 12 May 2026 | 10-Q |
| 29 Apr 2026 | 144 |
| 22 Apr 2026 | S-8 POS |
| 06 Apr 2026 | S-8 POS |
| 30 Mar 2026 |
Form 4: Macko Todd D, Chief Financial Officer
Sold 1,600 shares ($961) · Sold 43,400 shares ($24.4K) |
| 25 Mar 2026 |
Form 4: Grady Jason, Director
Sold 50,000 shares ($32.5K) |
| 11 Mar 2026 | 10-K |
| 04 Mar 2026 | 8-K: Entry into a Material Definitive Agreement |
| 06 Jan 2026 |
Form 4: DSS, Inc., 10% owner
Sold 115,600 shares ($63.5K) · Sold 45,400 shares ($24.5K) |
| 30 Dec 2025 | DEF 14C |
| 11 Dec 2025 | PRE 14C |
| 07 Nov 2025 | 10-Q |
Loading...
